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2-Aminoethoxydiphenylborate (2-APB) inhibits
release of phosphatidylserine-exposing
extracellular vesicles from platelets
Hao Wei1, Jessica E. Davies1 and Matthew T. Harper1
Abstract
Activated, procoagulant platelets shed phosphatidylserine (PS)-exposing extracellular vesicles (EVs) from their surface
in a Ca2+- and calpain-dependent manner. These PS-exposing EVs are prothrombotic and proinflammatory and are
found at elevated levels in many cardiovascular and metabolic diseases. How PS-exposing EVs are shed is not fully
understood. A clearer understanding of this process may aid the development of drugs to selectively block their
release. In this study we report that 2-aminoethoxydiphenylborate (2-APB) significantly inhibits the release of PS-
exposing EVs from platelets stimulated with the Ca2+ ionophore, A23187, or the pore-forming toxin, streptolysin-O.
Two analogues of 2-APB, diphenylboronic anhydride (DPBA) and 3-(diphenylphosphino)-1-propylamine (DP3A),
inhibited PS-exposing EV release with similar potency. Although 2-APB and DPBA weakly inhibited platelet PS
exposure and calpain activity, this was not seen with DP3A despite inhibiting PS-exposing EV release. These data
suggest that there is a further target of 2-APB, independent of cytosolic Ca2+ signalling, PS exposure and calpain
activity, that is required for PS-exposing EV release. DP3A is likely to inhibit the same target, without these other effects.
Identifying the target of 2-APB, DPBA and DP3A may provide a new way to inhibit PS-exposing EV release from
activated platelets and inhibit their contribution to thrombosis and inflammation.
Introduction
Platelets are the main cellular component of haemos-
tasis. They adhere, activate and aggregate at sites of vas-
cular injury, forming a haemostatic plug that prevents
blood loss. However, platelet activation on a ruptured
coronary atherosclerotic plaque is the main event in
coronary thrombosis, leading to unstable angina or
myocardial infarction1. Anti-platelet drugs are therefore
used to prevent coronary thrombosis in at-risk patients2,3.
During platelet activation, procoagulant platelets expose
phosphatidylserine (PS) in the outer leaflet of their plasma
membrane. PS is normally restricted to the inner leaflet by
an aminophospholipid translocase (‘flippase’). A high,
sustained increased in cytosolic Ca2+ concentration
([Ca2+]cyt) leads to inhibition of the flippase and activa-
tion of a non-selective phospholipid scramblase,
TMEM16F4–6. The result is net movement of PS to the
outer leaflet. PS forms a procoagulant surface for the
tenase and prothrombinase coagulation complexes,
increasing thrombin generation7–9.
Procoagulant platelets also release PS-exposing extra-
cellular vesicles (EVs). These are prothrombotic and
proinflammatory10,11. The levels of PS-exposing EVs are
increased in many cardiovascular and metabolic dis-
orders12–17, and platelets are the major source of circu-
lating PS-exposing EVs11,18. The pathological role of PS-
exposing EVs, and their elevation in a range of diseases,
makes them an attractive therapeutic target.
How PS-exposing EVs are shed from the plasma
membrane is not fully understood. A clearer under-
standing of this process may aid the development of
drugs to selectively block their release. PS exposure
itself may be important, as they are not shed from pla-
telets from Tmem16f−/− mice or from patients with
Scott Syndrome, a very rare bleeding disorder caused by
© The Author(s) 2020
OpenAccessThis article is licensedunder aCreativeCommonsAttribution 4.0 International License,whichpermits use, sharing, adaptation, distribution and reproduction
in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if
changesweremade. The images or other third partymaterial in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to thematerial. If
material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
Correspondence: Matthew T. Harper (mth29@cam.ac.uk)
1Department of Pharmacology, University of Cambridge, Cambridge, UK
Edited by I. Amelio
Official journal of the Cell Death Differentiation Association
12
34
56
78
90
()
:,;
12
34
56
78
90
()
:,;
1
2
3
4
5
6
7
8
9
0
()
:,;
12
34
56
78
90
()
:,;
lack of functional TMEM16F5,19. In addition, high
[Ca2+]cyt in procoagulant platelets activates the
Ca2+-dependent protease, calpain20,21. Calpain-
dependent cleavage of cytoskeletal proteins is also
necessary. However, little is known of the mechanism
beyond these events. Indeed, it is not clear whether any
events other than PS exposure and calpain activity are
required downstream of increased [Ca2+]cyt.
Platelets can be effectively stimulated to shed PS-
exposing EVs by Ca2+ ionophores, such as A23187, trig-
gering a high, sustained increase in [Ca2+]cyt. Although
not a physiological stimulus, by bypassing platelet recep-
tors and their proximal signalling cascades it can be used
to understand the downstream mechanisms of EV release.
PS-exposing EVs can be distinguished by their size and
their capacity to bind annexin V (AnV). During pre-
liminary experiments, we were surprised to find that 2-
aminoethoxydiphenylborate (2-APB) significantly inhib-
ited A23187-induced annexin V-positive (AnV+) EV
release. This was surprising since 2-APB is a cell-
permeable modulator of numerous ion channels, parti-
cularly Ca2+ channels, yet we expected the use of a Ca2+
ionophore to bypass any contribution of plasma mem-
brane or intracellular Ca2+ channels. Therefore, in this
study, we investigated the mechanism of how 2-APB
inhibits the release of AnV+ EVs from platelets. We find
that the effect of 2-APB does not depend on inhibition of
Ca2+ signalling, PS exposure or calpain activity. These
results indicate that events in addition to PS and calpain
activation are required for release of PS-exposing EVs and
suggest the existence of other potential targets to inhibit
this important pathological process.
Results
2-APB inhibits AnV+ EV release induced by the Ca2+
ionophore, A23187
In order to better understand the processes by which
platelets release PS-exposing EVs, platelets were stimu-
lated with the Ca2+ ionophore, A23187. This triggers
rapid Ca2+ entry, resulting in PS exposure and release of
PS-exposing EVs. PS exposure was detected using annexin
V (AnV) (Fig. 1a). AnV+ platelets and AnV+ EVs were
detected by flow cytometry. As we have previously dis-
cussed, this approach is likely to preferentially detect the
largest AnV+ EVs and to underestimate the total number
of EVs released22. However, it is still a rapid and effective
means of assessing AnV+ EV release.
Pre-treatment with 2-APB (100 µM) significantly
inhibited AnV+ EV release compared to platelets treated
with the vehicle (DMSO) at all concentrations of A23187
tested. In contrast, the percentage of AnV+ platelets was
only weakly affected (Fig. 1a–c). When 10 µM A23187
was used, 2-APB inhibited AnV+ EV release with a pIC50
of 4.45 ± 0.09 (IC50 approximately 35 µM; n= 5), with no
corresponding effect on platelet AnV+ binding (Fig. 1d).
To assess the reversibility of the inhibition, platelets
were treated with 2-APB or DMSO then washed by
centrifugation. The procedure of washing platelets by
centrifugation resulted in slightly greater sensitivity to
A23187 (pEC50 of 5.77 ± 0.20 for AnV
+ EV release prior
to washing; pEC50 of 6.16 ± 0.12 after washing). 2-APB-
treated platelets released significantly fewer AnV+ EVs
when stimulated with A23187. Notably, there was now no
difference in platelet AnV binding between 2-APB-treated
and DMSO-treated platelets at any concentration of
A23187 (Supplementary Fig. 1).
Together, these data indicate that 2-APB inhibits
A23187-induced AnV+ EV release. This action not rela-
ted to the weak inhibition of platelet PS exposure.
Structural analogues of 2-APB show differing effects on
AnV+ EV release
2-APB has many reported targets. To further char-
acterise its effects, we used a small panel of related,
commercially available compounds (Supplementary Fig.
2). The effects of these analogues on some 2-APB targets
has been previously described (Supplementary Table 1).
Some analogues had no effect on A23187-induced AnV+
EV release (Fig. 2). Phenylborinic acid (PBA) has the boron
atom attached to only one phenyl group and may be too
simple a fragment to effectively inhibit AnV+ EV release.
Since di-PBA is unstable23, we used the more stable ana-
logue, dimesitylborinic acid (DMBA), which has two phenyl
rings replaced by mesityl groups. This was also ineffective at
100 µM. It may be that analogues with a terminal B–OH are
ineffective and that a B–O core is required.
Two analogues that lack the boron atom were also
ineffective: 2,2-diphenyltetrahydrofuran (DPTHF), which
has a five-membered ring containing an oxygen atom,
similar to the ring form of 2-APB, but lacks a boron or
nitrogen atom, and diphenhydramine (DPHD), which is
similar to the linear form of 2-APB, but lacks the boron
atom and has two methyl groups attached to the
secondary amine.
In contrast, diphenylboronic anhydride (DPBA) and 3-
(diphenylphosphino)-1-propylamine (DP3A) both inhib-
ited AnV+ EV release. Both were of similar potency to 2-
APB. The pIC50 for DPBA was 4.55 ± 0.32 (IC50
approximately 28 µM; n= 5). The pIC50 for DP3A was
4.38 ± 0.14 (IC50 approximately 42 µM; n= 5). The
effectiveness of DPBA and DP3A indicates that neither
the amine group nor the boron atom is necessary for
inhibition. In addition, DPBA partially reduced the per-
centage of AnV+ platelets, whereas DP3A did not, sug-
gesting that the boron atom may be important for this
weak inhibition.
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Fig. 1 (See legend on next page.)
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The inhibitory effect of 2-APB is not through inhibition of
Ca2+ signalling
2-APB is known to modulate a variety of plasma
membrane channels that are expressed in platelets,
including Orai1, TRPC6 and Ca2+-activated K+ chan-
nels24–28. To determine whether any of these targets were
involved in the inhibitor effect of 2-APB, Cal-520-loaded
platelets were used to monitor the effect of A23187 and 2-
APB on cytosolic Ca2+ signalling. A23187 induced a rapid
increase in fluorescence (Fig. 3a). Surprisingly, 2-APB
inhibited this increase in fluorescence in a concentration-
dependent manner (Fig. 3a, b). Although DPBA also
inhibited the Cal-520 fluorescence in a concentration-
dependent manner, DP3A had no effect (Fig. 3a, b). This
is important as DP3A inhibited AnV+ EV release, sug-
gesting that there is no direct link between the inhibition
of Cal-520 fluorescence and inhibition of AnV+ EV
release. The analogues that did not affect AnV+ EV
release (PBA, DPTHF, DPHD, and DMBA) had no effect
on the A23187-induced increase in fluorescence (Fig. 3c).
Inhibition of Orai1 with Synta-66 (10 μM), TRPC6 with
SAR-7334 (1 μM) or the Na+–Ca2+ exchanger (NCX)
with SN-6 (50 μM), singly or combined, had no effect on
the A23187-induced increase in Cal-520 fluorescence,
AnV+ EV release or platelet AnV binding (Fig. 3d–f).
Since it was surprising that 2-APB affected A23187-
induced cytosolic Ca2+ signalling, we investigated whether
the effect on Cal-520 fluorescence might be an artefact
owing to a change in cytosolic pH. Addition of NH4Cl to
unstimulated Cal-520-loaded platelets, which is expected
to result in rapid intracellular alkalinisation, gave a rapid
increase in fluorescence. Similarly, addition of extracellular
NaOH also increased the fluorescence. Extracellular HCl
had little effect on the Cal-520 fluorescence in unstimu-
lated platelets (Fig. 4a). Although A23187 rapidly
increased Cal-520 fluorescence to a plateau, which is as
expected as the dye is likely to be saturated with Ca2+
under these conditions, this fluorescence could be further
increased by extracellular NH4Cl or NaOH. It could also
be decreased by extracellular HCl, suggesting that H+
enters stimulated platelets (Fig. 4b). Together, these data
show that Cal-520 fluorescence is highly sensitive to pH.
To determine whether 2-APB affects cytosolic pH,
platelets were loaded with the pH-sensitive fluorescent
dye, BCECF. NH4Cl rapidly increased BCECF fluores-
cence, indicating cytosolic alkalinisation, which slowly
reversed (Fig. 4c). HCl rapidly decreased BCECF fluores-
cence, indicating cytosolic acidification (Fig. 4c). How-
ever, neither 2-APB, nor any of the analogues tested,
significantly affected BCECF fluorescence (Fig. 4c, d). This
suggests that 2-APB does not affect cytosolic pH. More-
over, the effect of 2-APB and DPBA on Cal-520 fluores-
cence is not an artefact of decreased cytosolic pH.
Furthermore, altering cytosolic pH with NH4Cl or HCl
did not significantly affect A23187-induced AnV+ EV
release or platelet AnV binding (Fig. 4e, f). These data
indicate that a change in cytosolic pH does not account
for the inhibitory effect of 2-APB.
2-APB is also reported to block Ca2+-activated K+
channels28, which may be required for PS-exposing EV
release29. However, neither quinine (300 μM) nor tetra-
ethylammonium (TEA; 30mM), two non-selective block-
ers of Ca2+-activated K+ channels, inhibited AnV+ EV
release or platelet AnV binding (Supplementary Fig. 3).
2-APB, DBPA and DP3A inhibit AnV+ EV release from
permeabilised platelets
To determine whether the effect of 2-APB was due to
directly interfering with the action of A23187, a different
means of inducing AnV+ EV release was used. Platelets
were permeabilised with the pore-forming toxin,
streptolysin–O (SL–O). The efficiency of permeabilisation
was tested by loading platelets with calcein. SL–O treat-
ment led to loss of intracellular calcein. (Fig. 5a). Permea-
bilisation did not require extracellular Ca2+, though was
enhanced by it (Fig. 5b). CaCl2 addition to permeabilised
platelets triggered AnV+ EV release (Fig. 5c). AnV+ EV
release was inhibited by the calpeptin (140 µM), indicating
that calpain is required (Fig. 5c), which is similar to
A23187-induced AnV+ EV release (Fig. 5d and ref. 22).
AnV+ EV release from permeabilised platelets was
inhibited by 2-APB, DPBA and DP3A, but not the other
analogues (Fig. 5c, d). This is the same pattern of action as
seen with A23187-induced AnV+ EV release. None of the
(see figure on previous page)
Fig. 1 2-APB inhibits release of PS-exposing (AnV+) extracellular vesicles (EVs). a Washed platelets were treated with 2-APB (100 μM; 30 min) or
the solvent, DMSO, as control, then stimulated with the indicated concentration of A23187 for 10 min, after which samples were stained with anti-
CD41a-PerCP-Cy7, and annexin V-FITC to detect PS exposure. PerCP-Cy7 fluorescence was used to trigger acquisition of CD41+ events. The panels
show density plots of events from low density (blue) to high density (red) of forward scatter (FSC) and FITC fluorescence. Unstimulated platelets have
high FSC-A and low annexin V-FITC binding (LR). Stimulation with A23187 triggered PS exposure in platelets and release of PS-exposing (AnV+) EVs.
The vertical line separating left and right was defined by the FSC of 1 µm silica beads. The density plots are representative of data from five different
donors. b, c Platelets were stimulated with the indicated concentration range of A23187. Mean data (±s.e.m.; n= 5) are shown for AnV+ EVs (b) and
the percentage of platelets (>1 µm) binding AnV. Concentration–response curves were fitted with a four-parameter logistic equation. Data were
further analysed by two-way RM-ANOVA with Sidak’s post-test. **p < 0.01; ***p < 0.001 (n= 5). d Platelets were treated with a range of concentrations
of 2-APB prior to stimulation with 10 µM A23187 (n= 5).
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Fig. 2 Structural analogues of 2-APB show differing effects on AnV+ EV release. a, b Platelets were treated with the indicated analogue
(100 µM; 30 min), or DMSO as control, then stimulated with a concentration range of A23187. AnV+ EV release and platelet AnV binding were
determined as described in Fig. 1. Concentration–response curves were fitted with a four-parameter logistic equation. Data were further analysed by
two-way RM-ANOVA with Sidak’s post-test. *p < 0.05; **p < 0.01; ***p < 0.001 for comparison with DMSO-treated platelets. For clarity, in the right-
hand panel, statistical significance for DP3A is marked with † (††p < 0.01; †††p < 0.001) but also indicates comparison with DMSO-treated platelets. c, d
Platelets were treated with a concentration range of DPBA (c) or DP3A (d) prior to stimulation with A23187 (10 µM).
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Fig. 3 2-APB, DPBA and DP3A reduce Cal-520 fluorescence. a Representative traces of Cal-520-loaded platelets treated as indicated then
stimulated with A23187 (10 µM; black arrowhead), expressed as Cal-520 fluorescence normalised to the fluorescence prior to stimulation (F/F0).
b Mean (±s.e.m.; n= 5) of maximum F/F0 in each condition, as a percentage of DMSO-treated platelets. c Maximum F/F0 for the inactive analogues
(line indicated mean). d Cal-520-loaded platelets were treated with SAR-7334 (1 µM), SN-6 (50 µM) and Synta-66 (10 µM), individually or combined, as
indicated, before stimulation with A23187 (10 µM; black arrowhead). The traces are representative of five independent experiments. e, f AnV+ EV
release and platelet AnV binding in samples treated with these inhibitors. No statistically significant difference was observed compared to platelets
treated with the solvent, DMSO (in each, one-way RM-ANOVA; n= 5).
Wei et al. Cell Death Discovery            (2020) 6:10 Page 6 of 15
Official journal of the Cell Death Differentiation Association
active drugs inhibited calcein loss from SL–O-permeabi-
lised platelets (Fig. 5e)
2-APB and DPBA partially inhibits calpain activation, but
DP3A does not
Calpain is required for AnV+ EV release following
A23187 or SL–O treatment. Platelet stimulation with
A23187 resulted in cleavage of the calpain substrates,
talin, ATP8A1, PTP1C and caspase-3, which was pre-
vented by pre-treatment with calpeptin (Fig. 6a). For
example, A23187 reduced the presence of the highest
talin band to 8.5 ± 3.4% of unstimulated (DMSO-treated)
samples (n= 5), whereas in the presence of calpeptin, this
band was not significantly changed to 96.7 ± 6.1% of
Fig. 4 2-APB does not inhibit AnV+ EV release by altering cytosolic pH. a Cal-520-loaded platelets were treated with HCl (10 mM), NaOH
(10mM) or NH4Cl (100mM) at the point indicated by the dashed line. b Cal-520-loaded platelets were stimulated with A23187 (10 µM; black
arrowhead) followed by HCl, NaOH or NH4Cl (dashed line). The traces are representative of five independent experiments. c Platelets were loaded
with the pH-sensitive dye, BCECF. HCl, NH4Cl, 2-APB or its vehicle, DMSO, were added at the dashed line. d Quantification of the change in BCECF
fluorescence within 1min of addition of the compounds indicated. The line shows the mean. Data with each treatment were compared to DMSO-
treated platelets by one-way RM-ANOVA, with Dunnett’s post-test. *p < 0.05; ***p < 0.001. e, f Platelets were treated with NH4Cl or HCl prior to
stimulation with A23187. Data are mean ± s.e.m. (n= 5). No statistically significant differences were observed compared to platelets treated with the
solvent, HBS (two-way RM-ANOVA).
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Fig. 5 (See legend on next page.)
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unstimulated, calpeptin-treated samples. Likewise, sti-
mulation with A23187 led to the presence of a lower band
(approximately 30 kDa) detected by the anti-caspase-3
antibody, consistent with previous reports30. However, in
calpeptin-treated samples, stimulation of A23187 led to a
barely detectable band, only 4.4 ± 1.0% (n= 5) of the band
in DMSO-treated, A23187-stimulated samples. 2-APB
(100 µM) also partially inhibited the cleavage of these
substrates. In 2-APB-treated samples, A23187 reduced
the highest band to 57.0 ± 11.0% compared to DMSO,
unstimulated samples (p < 0.05; also p < 0.05 compared to
DMSO, A23187-stimulated; one-way ANOVA with
Tukey’s multiple comparisons test). Similarly, in 2-APB-
treated samples, the lower caspase-3 band was only 40.8 ±
8.3% of that in DMSO-treated, A23187-stimulated sam-
ples (p < 0.05; n= 5). The 2-APB analogues were then
tested for their ability to prevent the cleavage of two of
these substrates, talin and caspase-3. Of the 2-APB ana-
logues tested, DPBA also partially inhibited the cleavage
of talin and capase-3, but DP3A, PBA, DMBA, DPHD and
DPTHF had no effect (Fig. 6b).
2-APB also inhibits AnV+ EV release from endothelial cells
To determine whether the inhibitory effect of 2-APB
was restricted to platelets, human umbilical vein endo-
thelial cells (HUVECs) were stimulated with A23187
(10 μM), resulting in AnV+ binding to HUVECs and
release of AnV+ EVs (Fig. 7a). AnV+ EV release was
prevented by calpeptin, indicating that it is dependent on
calpain activity (Fig. 7a). Pre-treatment with 2-APB
(100 μM) inhibited the release of AnV+ EVs but not
HUVEC AnV binding. The pIC50 for inhibition of AnV
+
EV release was 5.88 ± 0.21 (Fig. 7d; n= 5), showing that 2-
APB is more potent in HUVEC than platelets. The same
range of 2-APB analogues was then tested (Fig. 7b, c).
PBA unexpectedly increased AnV+ EV release. DMBA
caused a significant loss of HUVEC viability, which may
explain the increase in AnV+ EV release that it caused,
and was not used further (Fig. 7c). AnV+ EV release was
inhibited by DPBA (Fig. 7f; pIC50= 6.03 ± 0.11; n= 5) and
DP3A (Fig. 7e; pIC50= 5.52 ± 0.32), as in platelets.
However, in contrast to platelets, DPTHF also inhibited
AnV+ EV release (Fig. 7g; pIC50= 5.68 ± 0.20). DPHD
also inhibited AnV+ EV release, but only at 100 μM.
These data suggest that the pharmacology of AnV+ EV
release from HUVEC is similar, but not identical, to that
of platelets.
Discussion
PS-exposing EVs released by activated platelets are
prothrombotic and proinflammatory11, and so inhibiting
their release may be a beneficial therapeutic approach31.
However, little is known about the mechanisms that lead
to their release and there are few drugs that can selectively
inhibit this process. In this study, we demonstrate that 2-
APB, a widely used Ca2+ channel modulator, inhibits PS-
exposing EV release. This is not through inhibition of the
major pathways currently known to be required for
release of PS-exposing EVs and is not through inhibition
of currently known targets of 2-APB. Although 2-APB
itself is insufficiently selective or potent to be a useful
therapeutic inhibitor of EV release, our results suggest the
existence of a potential target. Future identification of this
target may aid the development of therapeutic drugs that
prevent the release of PS-exposing EVs.
Although little is known about the mechanisms of PS-
exposing EV release from activated platelets, it requires a
high, sustained increase in [Ca2+]cyt
32–34. This can be
triggered by a Ca2+ ionophore. Although this is not a
physiological stimulation, it should bypass intracellular
Ca2+ release channels, such as IP3Rs, and plasma mem-
brane Ca2+ entry channels, such as Orai1 and TRPC6,
major targets for 2-APB in platelets24–26,35,36. Indeed, this
is why we were not expecting 2-APB to inhibit A23187-
induced release of AnV+ EVs. In contrast, if physiological
activators were used, such as thrombin plus cross-linked
collagen-related peptide, the increase in [Ca2+]cyt would
require these Ca2+ channels37,38. The multiple effects of
2-APB mean that it would not itself be a suitable ther-
apeutic, although understanding its mechanism of action
may help us to understand the mechanisms that underlie
the release of PS-exposing EVs from platelets.
(see figure on previous page)
Fig. 5 2-APB, DPBA and DP3A inhibit streptolysin–O-induced AnV+ release. a, b Platelets were loaded with calcein then treated with reduced
streptolysin–O (SL–O) in the presence or absence of extracellular CaCl2. Representative density plots are shown in (a). Unstimulated platelets have
high calcein fluorescence. SL–O treated platelets have lost calcein. b Mean ± s.e.m. (n= 5) of percentage of platelets that lost calcein fluorescence at
various SL–O concentrations in the presence or absence of extracellular CaCl2. SL–O was more effective in the presence of extracellular CaCl2 (***p <
0.001; two-way RM-ANOVA with Sidak’s post-test). c Platelets (without calcein) were treated with SL–O then CaCl2 added. AnV
+ EVs were released in a
similar pattern to A23187-stimulated platelets. Where indicated, platelets had been pre-treated with calpeptin (140 µM; 30 min) or 2-APB, DPBA or
DP3A (all 100 µM). Density plots are representative of five independent experiments. d AnV+ EV release from platelets stimulated with A23187 or
SL–O, pre-treated as indicated. **p < 0.01 (calpeptin vs. DMSO, A23187 stimulated; paired t test); †††p < 0.001 (treatments indicated vs. DMSO, SL–O-
permeabilised platelets; one-way RM-ANOVA; other treatments were not significantly different p > 0.05). e Calcein-loaded platelets were treated with
2-APB, DPBA or DP3A, then permeabilised with SL–O. The percentage of platelets negative for calcein fluorescence in five independent experiments
is shown. *p < 0.05 compared to DMSO (one-way RM-ANOVA with Dunnett’s post-test).
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Increased [Ca2+]cyt activates the Ca
2+-dependent
scramblase, TMEM16F, leading to PS exposure, and
activation of the protease, calpain. Both events are
required for PS-exposing EV release34. It is not likely that
2-APB directly inhibits TMEM16F, as platelet AnV
binding was largely unaffected under conditions where
AnV+ EV release was completely inhibited. Moreover,
although a small inhibition of platelet AnV binding was
observed when 2-APB was present, this was fully reversed
by washing the platelets, whereas the inhibition of AnV+
EV release was not so readily reversed.
Since 2-APB has many identified targets, we char-
acterised a small set of related molecules that might have
differing pharmacology. Two analogues, DPBA and
DP3A, retained efficacy with similar potency to 2-APB.
The other analogues showed no inhibitory action at
100 µM in platelets. These observations indicated that
neither the secondary amine, nor the boron atom, are
absolutely required for the inhibitory action. They also
suggest that the effect of 2-APB is not through inhibition
of store-operated Ca2+ entry (SOCE), since DPTHF and
DMBA (and to a small extent DPHD) have been shown to
Fig. 6 Calpain activity is inhibited by 2-APB and DPBA, but not DP3A. a Platelets were treated with the calpain inhibitor, calpeptin (140 µM), 2-
APB (100 µM) or the vehicle (DMSO) prior to stimulation with A23187 as indicated, then lysed. Proteins were separated by SDS-PAGE. Talin, ATP8A1,
PTP1C and caspase-3 were detected with specific antibodies. The membranes were then stripped and re-probed with anti-CD41-antibody or anti-
GADPH antibody, as indicated. A23187-triggered protein cleavage was inhibited by calpeptin and partially inhibited by 2-APB. The blots are
representative of five independent experiments. b Platelets were treated with the indicated analogues prior to stimulation with A23187. The blots are
representative of five independent experiments.
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Fig. 7 (See legend on next page.)
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inhibit SOCE39 but had no effect on AnV+ EV release.
Interestingly, the pattern of active and inactive analogues
was similar to that reported for interleukin (Il)-1β release
from mouse macrophages40 (see Supplementary Table 1).
In that study the effect was attributed to inhibition of the
NLRP3 inflammasome. However, since Il-1β may be
released in EVs41, inhibition of EV release could con-
tribute to the inhibition of Il-1β release.
Moreover, these analogues provided a small toolkit to
help explore the mechanism of action of 2-APB. AnV+ EV
release showed the same pattern of sensitivity to 2-APB
analogues whether the process was triggered by A23187
in intact platelets or by Ca2+ addition to SL–O-permea-
bilised platelets. This supports the assumption that the
two stimuli were triggering the same process. It also
indicates that the lack of action of PBA, DMBA, DPHD
and DPTHF was not due to insufficient plasma membrane
permeability.
2-APB is unlikely to inhibit AnV+ EV release through
an action on Ca2+ channels. This is shown by several lines
of evidence. The most direct evidence is the observation
that 2-APB also inhibited AnV+ EV release from SL–O-
permeabilised platelets. SL–O permeabilisation allowed
calcein to completely leak from the platelets, and has been
previously used to introduce antibodies into platelets42.
Extracellular Ca2+ rapidly triggered AnV+ EV release
from SL–O-permeabilised platelets in a calpain-
dependent manner. Together, these data indicate that
there is direct continuity between the extracellular and
intracellular environment. 2-APB did not prevent calcein
leakage from SL–O-permeabilised platelets, indicating
that it did not affect this continuity. Therefore, it is
unlikely that 2-APB inhibits AnV+ EV release by inhi-
biting Ca2+ flux between the extracellular and intracel-
lular environment. Consistent with this conclusion,
inhibition of Orai1 or TRPC6 (or NCX, which acts in
reverse-mode downstream of TRPC637) did not affect
AnV+ EV release. Moreover, it is unlikely that other ion
fluxes, such as Na+, K+ or Cl− are required. For example,
Ca2+-activated K+ channels have previously been pro-
posed to regulate platelet PS exposure and subsequent
AnV+ EV release29, and these channels may be inhibited
by 2-APB28. However, not only is it unlikely that K+ flux
plays an important role once the platelets have been
permeabilised, but also two unrelated, non-selective
blockers of Ca2+-activated K+ channels had no effect on
A23187-induced AnV+ EV release. Therefore, it is likely
that 2-APB has a target in AnV+ EV release that is
separate to plasma membrane ion channels.
At first sight, our observation that 2-APB inhibits the
A23187-induced increase in Cal-520 fluorescence appears
to lead to the opposite conclusion, as it suggests that 2-
APB inhibits the increase in [Ca2+]cyt. It is unclear whe-
ther this is a real inhibition of [Ca2+]cyt, or an artefactual
effect on Cal-520 fluorescence. It is possible that 2-APB
and DPBA affect the fluorescence spectrum of Cal-520 (in
a manner that DP3A does not). We first considered
whether 2-APB might induce cytosolic acidification, as it
has been previously shown to rapidly acidify Jurkat
T cells43, though this required action on (unidentified)
membrane proteins and may be a cell-type specific effect.
Many Ca2+-sensitive fluorescent dyes are acutely sensitive
to pH and our data show that Cal-520 is also sensitive to
pH. However, 2-APB did not affect intracellular pH,
assessed by BCECF fluorescence, suggesting that cytosolic
acidification does not explain the reduced Cal-520 fluor-
escence. In addition, treatments that did alter intracellular
pH (extracellular addition of NH4Cl or HCl) did not affect
AnV+ EV release. This indicates that 2-APB does not
inhibit AnV+ EV release by altering intracellular pH.
It is possible that 2-APB does inhibit the A23187-
induced increase in [Ca2+]cyt, rather than artefactually
decrease Cal-520 fluorescence, though the mechanisms
that could be involved are unclear. The ionophore action
of A23187 itself could be directly inhibited, which could
be tested by using alternative approaches to increase
[Ca2+]cyt (e.g. ionomycin, thapsigargin). Our data indicate
that the action of 2-APB on A23187-induced Cal-520
fluorescence does not involve inhibition of Orai1 or
TRPC6, the major Ca2+ entry channels in platelets. One
possibility is that platelets contain two intracellular Ca2+
stores, the dense tubular system and acidic Ca2+ stores,
such as lysosomes44. The latter are relatively insensitive to
Ca2+ ionophores45 and may require a 2-APB-sensitive
process for their depletion. Inhibition of [Ca2+]cyt sig-
nalling could account for the weak inhibition of PS
(see figure on previous page)
Fig. 7 2-APB, DPBA and DP3A inhibit AnV+ EV release from HUVEC. a HUVEC were stimulated with A23187 (10 μM) as described in “Methods”.
The panels show acquired events in the medium, stained with anti-CD31-APC and annexin V-FITC, using APC fluorescence to trigger acquisition. For
comparison, some samples were pre-treated with calpeptin or 2-APB prior to stimulation. The density plots are representative of five independent
experiments. b HUVEC were pretreated with 2-APB or one of its analogues then stimulated with A23187. AnV+ EV release into the medium in
expressed as a percentage of AnV+ EV released in matched samples treated with the vehicle, DMSO, prior to A23187. **p < 0.01, ***p < 0.001 vs.
DMSO; one-way ANOVA with Holm-Sidak’s post-test (n= 5). (c) HUVEC survival following treatment with 2-APB or its analogues was determined
using a luminescence assay. ***p < 0.001. d–g Platelets were treated with a concentration range of the indicated analogue prior to stimulation with
prior to stimulation with A23187 (10 µM). AnV+ EV release is expressed as a percentage of matched samples treated with the vehicle, DMSO, prior to
A23187 (n= 5).
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exposure and calpain activity by 2-APB and DPBA.
Although PS exposure and calpain activity are required
for PS-exposing EV release5,20,22,46, these small inhibitory
effects cannot account for the inhibition of AnV+ EV
release by 2-APB, since the phosphorus-containing ana-
logue, DP3A, had no effect on Cal-520 fluorescence,
platelet AnV binding or calpain activity, yet inhibited
AnV+ EV release with similar potency. These data suggest
that there is a further target of 2-APB, independent of
[Ca2+]cyt, PS exposure and calpain activity, that is
required for AnV+ EV release (Fig. 8). DP3A is likely to
inhibit the same target, without these other effects, and
may be a better scaffold from which to develop a more
selective inhibitor of EV release.
To determine whether the action of 2-APB was specific
to AnV+ EV release from platelets, we also examined
AnV+ EV release from HUVECs. Again, we used A23187
to directly increase [Ca2+]cyt, aiming to bypass any inhi-
bition of Ca2+ channels by 2-APB. Endothelial cells
release EVs during activation and apoptosis47. Whether
the mechanisms underlying the release of EVs under these
different conditions are the same in unclear. In our
experimental setting, A23187 rapidly triggered AnV
binding to HUVEC and release of AnV+ EVs. The latter
was blocked by 2-APB. However, although AnV+ EV
release from HUVEC was also inhibited by DPBA and
DP3A, as in platelets, these drugs were more potent in
HUVEC than in platelets. Moreover, AnV+ EV release
from HUVEC was also inhibited by DPTHF. This suggests
that the target of 2-APB in HUVEC and platelets may be
similar but are not identical. As a tentative speculation, it
may involve different isoforms of a protein family. This
difference opens the possibility of being able to selectively
inhibit PS-exposing EV release from different cells.
Conclusion
PS-exposing EVs are released by stimulated platelets in
a Ca2+/calpain-dependent manner. Although PS-exposing
EVs are likely to contribute to a range of prothrombotic
and proinflammatory diseases, there are few drugs avail-
able to block their release. 2-APB inhibits the release of
AnV+ EVs. Identifying the target of 2-APB, DPBA and
DP3A may provide a new way to inhibit AnV+ EV release
from activated platelets and inhibit their contribution to
thrombosis and inflammation.
Methods
Washed platelet preparation
Blood was drawn by venepuncture into sodium citrate
(3.2% v/v) from healthy, drug-free volunteers, who had given
written, informed consent in accordance with the Declara-
tion of Helsinki. Use of human blood for these experiments
was approved by the Human Biology Research Ethics
Committee, University of Cambridge. Acid citrate dextrose
(ACD; 85mM tri-sodium citrate, 71mM citric acid, 111mM
D-glucose) was added (1:7 v/v) and platelet-rich plasma (PRP)
separated by centrifugation (200g, 10min). Prostaglandin E1
(100 nM) and apyrase (Grade VII; 0.02 U/ml) were added to
PRP to prevent platelet activation during preparation. Where
required, platelets were incubated with either Cal-520-
acetoxymethyl (AM) or calcein-AM (both 1 µM; 10min).
Platelets were pelleted from PRP by centrifugation (600g,
10min) and resuspended in HEPES-buffered saline (in mM:
10 HEPES, 135 NaCl, 3 KCl, 0.34 NaH2PO4, 1 MgCl2·6H2O,
pH 7.4; supplemented with 0.9mg/ml D-glucose) at 5 × 107
platelets/ml. Platelets were rested (30 °C, 30min) prior to
treatment with inhibitors or stimulation. CaCl2 (2mM) was
added immediately prior to simulation.
Flow cytometry analysis
Following stimulation, samples were stained with FITC-
conjugated annexin V (eBioscience, ThermoFisher, UK), to
detect exposed PS, (FL1), unless otherwise indicated, and PE-
Cy7-conjugated anti-CD41 antibody (eBioscience, Thermo-
Fisher, UK), to distinguish platelet-derived events. Samples
were analysed using a BD Accuri C6 flow cytometer. PE-Cy7
fluorescence (FL3) was used to trigger event acquisition. PS-
positive platelet-derived EVs were defined as CD41+/annexin
V+ events that were smaller than 1 µm. The 1 µm gate was
set in forward scatter using 1 µm silica beads22.
Immunoblotting
Platelet proteins were detected in platelet lysates by
sodium dodecyl sulfate–polyacrylamide gel electrophoresis
Fig. 8 PS-exposing EV release is inhibited by 2-APB analogues.
Summary of the targets of 2-APB, DPBA and DP3A. All three drugs
inhibit PS-exposing EV release. 2-APB and DPBA also affect Cal-520
fluorescence, which may indicate inhibition of Ca2+ signalling, or may
be artefactual (see “Discussion”). Inhibited Ca2+ signalling may explain
the weak inhibition of Ca2+ effectors, TMEM16F and calpain, with 2-
APB and DPBA. In contrast, DP3A does not show any inhibition of
TMEM16F or calpain activity.
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and immunoblotting, essentially as described previously22.
The primary antibodies used were: anti-talin antibody
(clone 8D4; T3287; from Sigma Aldrich, Poole, Dorset, UK)
anti-PTP1C (610125; BD Biosciences); anti-ATP8A1
(21565-1-AP; Proteintech Europe, Manchester, UK); anti-
CD41 antibody (ab134131; from Abcam, Cambridge, UK);
and anti-caspase3 (9662) and anti-GAPDH (2118; from Cell
Signalling Technology; Davers MA, USA). The secondary
antibodies used were horseradish peroxidase-conjugated
anti-rabbit IgG (7074) or anti-mouse IgG (7076; both Cell
Signalling Technology).
Measurement of cytosolic Ca2+ concentration ([Ca2+]cyt)
and pH
Cal-520-loaded platelets were stimulated in black-walled
microplates at 30 °C. Fluorescence (excitation: 492 nm;
emission: 520 nm) was recorded using a FLUOStar
OMEGA (BMG LabTech). BCECF-loaded platelets were
stimulated in black-walled microplates at 30 °C. Fluores-
cence (excitation: 485 nm; emission: 520 nm).
Measurement of endothelial EV release and PS exposure
HUVEC (Promocell, c-12203), were cultured in endo-
thelial cell growth medium (PromoCell; c-22010), sup-
plemented with 35 µg/mL gentamycin and endothelial cell
growth supplements (Promocell, c-39215) at 5% CO2 and
37 °C. HUVEC were routinely tested for mycoplasma
contamination. HUVEC were seeded into 24-well plates
(at 1.5 × 105/well) 24 h prior to drug treatment. HUVEC
were washed to remove cell debris and constitutively
released EVs then pre-treated for 30min in endothelial cell
growth media with the appropriate inhibitor. After this,
media was replaced with HEPES-buffered saline supple-
mented with glucose (0.9 mg/ml), CaCl2 (2mM), A23187
(10 μM) and inhibitor for 10min. Following stimulation,
both the EV-rich medium and trypsinized endothelial cells
were collected and stained with APC-conjugated anti-
CD31 (eBioscience,ThermoFisher, UK). Samples were
analysed using a BD Accuri C6 flow cytometer. APC
fluorescence (FL4) was used to trigger event acquisition
and identify endothelial (or endothelial-derived EV)
events. to determine EV count and cellular PS exposure,
respectively. PS-exposing endothelial-derived EVs were
defined as CD31+/annexin V+ events that were smaller
than 1 µm in an analogous manner to platelet-derived EVs.
Endothelial viability
To determine inhibitor toxicity, HUVEC were seeded in
a 96-well clear-bottom plate at 1.5 × 104 cells/well, 24 h
prior to treatment. Endothelial cells were treated as
described above. The cell viability assay (Promega, UK
G7572) was conducted according to the manufacturer’s
instruction to evaluate the ATP content.
Data presentation and statistical analysis
Data are reported as mean ± standard error of mean
(SEM) from at least five independent platelet prepara-
tions. N= 5 was chosen based on the mean and standard
deviation of AnV+ EV release in preliminary experiments,
in order to detect a 50% reduction with 80% power at p <
0.05. Data were compared using one-way or two-way
repeat measures analysis of variance (RM-ANOVA), as
appropriate, in GraphPad Prism v7. No samples were
excluded from analysis. Concentration–response curves
were fitted using a four-parameter logistical equation.
This was also used to estimate pIC50 (i.e., −log(IC50)).
Source of materials
All reagents, including the 2-APB analogues, were
obtained from Sigma Aldrich (Poole, Dorset, UK) unless
otherwise stated. A23187 was from Acros Organics
(Fisher Scientific, UK). 2-APB was from Cayman Chemi-
cals (Cambridge Bioscience, Cambridge, UK). SAR-7334
and SN-6 were from Tocris (Bristol, UK). Calcein and
BCECF were from ThermoFisher Scientific. Cal-520 was
from AAT Bioquest (Sunnyvale CA, USA).
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